Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A.

Patients with severe coagulation factor VIII deficiency require frequent infusions of human factor VIII (hFVIII) concentrates to treat life-threatening hemorrhages. Because these patients are immunologically hFVIII-naive, a significant treatment complication is the development of inhibitors or circulating alloantibodies against hFVIII, which bind the replaced glycoprotein, increase its plasma clearance, and inhibit its activity, preventing subsequent treatments from having a therapeutic effect. A genetic approach toward the induction of immunologic unresponsiveness to hFVIII has the conceptual advantage of a long-term, stable elimination of undesired immune responses against hFVIII. Here, we report that in a factor VIII (FVIII)-deficient mouse model for severe hemophilia A, genetic modification of donor bone marrow cells with a retroviral vector encoding hFVIII, and transplant to hemophiliac mouse recipients, results in the induction of immune tolerance to FVIII in 50% of treated animals after immunization with hFVIII, despite the fact that hFVIII protein or activity is undetectable. In tolerized animals, the titers of anti-hFVIII binding antibodies and of hFVIII inhibitor antibodies were significantly reduced, and there was evidence for hFVIII unresponsiveness in CD4(+) T cells. Importantly, the plasma clearance of hFVIII was significantly decreased in tolerized animals and was not significantly different from that seen in a FVIII-naive hemophiliac mouse. This model system will prove useful for the evaluation of genetic therapies for hFVIII immunomodulation and bring genetic therapies for hFVIII tolerance closer to clinical application for patients with hemophilia A.

[1]  H. Ochs,et al.  Full immunologic reconstitution following nonconditioned bone marrow transplantation for canine X-linked severe combined immunodeficiency. , 1997, Blood.

[2]  G. Szot,et al.  Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning , 1997, Nature Medicine.

[3]  J. Yewdell,et al.  Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. , 1997, Immunity.

[4]  I. Scharrer,et al.  The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. , 1997, Blood.

[5]  D. Scott,et al.  Both resting and activated B lymphocytes expressing engineered peptide-Ig molecules serve as highly efficient tolerogenic vehicles in immunocompetent adult recipients. , 1997, Journal of immunology.

[6]  Elias T. Zambidis,et al.  Genetically Transferred Central and Peripheral Immune Tolerance via Retroviral-Mediated Expression of Immunogenic Epitopes in Hematopoietic Progenitors or Peripheral B Lymphocytes , 1997, Molecular medicine.

[7]  H. Kazazian,et al.  Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. , 1996, Blood.

[8]  V. Engelhard,et al.  Use of gene therapy to suppress the antigen-specific immune responses in mice to an HLA antigen. , 1996, Transplantation.

[9]  D. Brettler.  8 Inhibitors in congenital haemophilia , 1996 .

[10]  H. Malech,et al.  Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy. , 1996, Blood.

[11]  H. Pircher,et al.  Prevention of autoimmune disease by retroviral-mediated gene therapy. , 1995, Journal of immunology.

[12]  R. Morgan,et al.  Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. , 1995, Human gene therapy.

[13]  E. Saenko,et al.  A Mechanism for Inhibition of Factor VIII Binding to Phospholipid by von Willebrand Factor (*) , 1995, The Journal of Biological Chemistry.

[14]  S. Boggs,et al.  A minimal conditioning approach to achieve stable multilineage mouse plus rat chimerism. , 1995, Transplant immunology.

[15]  D Orlic,et al.  Pluripotent hematopoietic stem cells contain high levels of mRNA for c-kit, GATA-2, p45 NF-E2, and c-myb and low levels or no mRNA for c-fms and the receptors for granulocyte colony-stimulating factor and interleukins 5 and 7. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S. Antonarakis,et al.  Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A , 1995, Nature Genetics.

[17]  D. Sachs,et al.  Specific unresponsiveness to a retrovirally-transferred class I antigen is controlled through the helper pathway. , 1995, Journal of immunology.

[18]  M. Kaleko,et al.  In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. , 1995, Human gene therapy.

[19]  I. Pastan,et al.  Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. , 1992, Science.

[20]  N. Ciavarella,et al.  Frequency of inhibitors in haemophiliacs , 1992, The Lancet.

[21]  W. Kreuz,et al.  Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs , 1992, The Lancet.

[22]  D. Harrison,et al.  Most primitive hematopoietic stem cells are stimulated to cycle rapidly after treatment with 5-fluorouracil. , 1991, Blood.

[23]  A. Nienhuis,et al.  Survival and retrovirus infection of murine hematopoietic stem cells in vitro: effects of 5-FU and method of infection. , 1991, Experimental hematology.

[24]  S. Goff,et al.  Retroviral Gene Transfer Using Safe and Efficient Packaging Cell Lines , 1990, Annals of the New York Academy of Sciences.

[25]  T. Sundt,et al.  Specific tolerance induction across a xenogeneic barrier: production of mixed rat/mouse lymphohematopoietic chimeras using a nonlethal preparative regimen , 1990, The Journal of experimental medicine.

[26]  I. Lemischka,et al.  Clonal and systemic analysis of long-term hematopoiesis in the mouse. , 1990, Genes & development.

[27]  M. Bender,et al.  Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region , 1987, Journal of virology.

[28]  S. Antonarakis,et al.  Molecular genetics of hemophilia A in man (factor VIII deficiency). , 1987, Molecular biology & medicine.

[29]  R. Lawn,et al.  Distribution of factor VIII mRNA and antigen in human liver and other tissues , 1985, Nature.

[30]  B. Keyt,et al.  Structure of human factor VIII , 1984, Nature.

[31]  I. Sussman,et al.  Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. , 1977, The Journal of clinical investigation.

[32]  P. Matzinger.  Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[33]  H. Auchincloss,et al.  Mechanisms of transplantation tolerance. , 1994, Annual review of immunology.

[34]  A. Nienhuis,et al.  Specific prolongation of skin graft survival following retroviral transduction of bone marrow with an allogeneic major histocompatibility complex gene. , 1993, Transplantation.